Group 1 - Addex Therapeutics will release its Q1 2025 Financial Results on June 19, 2025, followed by a business update and product pipeline review during a teleconference and webcast [1][2] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) [2] - Addex Therapeutics focuses on developing novel small molecule allosteric modulators for neurological disorders, with its lead drug candidate, dipraglurant, under evaluation for brain injury recovery [3] Group 2 - Addex's partner, Indivior, has selected a GABAB PAM drug candidate for substance use disorders and completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025